New Findings Reported from Villejuif Describe Advances in Medullary Thyroid Cancer [Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A...].

A new report from Villejuif, France presents fresh data on medullary thyroid cancer. The study investigated the safety and efficacy of nintedanib, a triple-angiokinase inhibitor, as a second-line therapy for patients with differentiated or medullary thyroid cancer that had progressed after first-line therapy. The study found that nintedanib did not show a clinically significant improvement in progression-free survival compared to a placebo for patients with pretreated thyroid cancer. Adverse events were more common in patients receiving nintedanib. Further research is needed in this area. [Extracted from the article]